Back to today’s briefing

Story perspectives

Novo Nordisk Launches Wegovy HD Amidst Rising Competition

4/7/2026

29 5 Full Breakdown

Summary

Story summary

Novo Nordisk announced Wegovy HD, a 7.2-milligram injection, is available in the U.S. under the FDA's National Priority Review Voucher program.
Cash-paying patients pay $399 per month.
Commercially insured patients may pay as little as $25.
Novo Nordisk plans to introduce a subscription plan for Wegovy HD as competition intensifies with Eli Lilly and Company's Zepbound and Foundayo.

1 of 1

Story summary

Novo Nordisk announced Wegovy HD, a 7.2-milligram injection, is available in the U.S. under the FDA's National Priority Review Voucher program.
Cash-paying patients pay $399 per month.
Commercially insured patients may pay as little as $25.
Novo Nordisk plans to introduce a subscription plan for Wegovy HD as competition intensifies with Eli Lilly and Company's Zepbound and Foundayo.